CORT - Corcept Therapeutics Incorporated Stock Price, News & Analysis

$17.75 0.17 (0.97 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$17.58
Today's Range$17.08 - $17.82
52-Week Range$6.70 - $20.77
Volume810,100 shs
Average Volume1.10 million shs
Market Capitalization$2.03 billion
P/E Ratio60.62
Dividend YieldN/A
Beta2.04

About Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:CORT
CUSIP21835210

Debt

Debt-to-Equity RatioN/A
Current Ratio3.85%
Quick Ratio3.70%

Price-To-Earnings

Trailing P/E Ratio60.62
Forward P/E Ratio37.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$81.32 million
Price / Sales24.91
Cash Flow$0.07 per share
Price / Cash236.89
Book Value$0.76 per share
Price / Book23.36

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$0.29
Net Income$8.14 million
Net Margins27.28%
Return on Equity58.17%
Return on Assets41.48%

Miscellaneous

Employees103
Outstanding Shares114,120,000

Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)

What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics Incorporated's earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.02. The biotechnology company had revenue of $42.70 million for the quarter, compared to analyst estimates of $41.64 million. Corcept Therapeutics Incorporated had a return on equity of 58.17% and a net margin of 27.28%. The business's revenue for the quarter was up 96.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.02 EPS. View Corcept Therapeutics Incorporated's Earnings History.

When will Corcept Therapeutics Incorporated make its next earnings announcement?

Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Corcept Therapeutics Incorporated.

Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?

4 brokerages have issued 1-year price targets for Corcept Therapeutics Incorporated's shares. Their forecasts range from $7.00 to $30.00. On average, they expect Corcept Therapeutics Incorporated's stock price to reach $19.25 in the next year. View Analyst Ratings for Corcept Therapeutics Incorporated.

Who are some of Corcept Therapeutics Incorporated's key competitors?

Who are Corcept Therapeutics Incorporated's key executives?

Corcept Therapeutics Incorporated's management team includes the folowing people:

  • James N. Wilson, Independent Chairman of the Board (Age 73)
  • Joseph K. Belanoff M.D., President, Chief Executive Officer, Director (Age 59)
  • Gary Charles Robb, Chief Financial Officer, Secretary (Age 54)
  • Robert S. Fishman M.D., Chief Medical Officer (Age 55)
  • G. Leonard Baker Jr., Independent Director (Age 74)
  • Daniel M. Bradbury, Independent Director (Age 56)
  • Renee D. Gala, Independent Director (Age 45)
  • David L. Mahoney, Independent Director (Age 62)
  • Daniel N. Swisher Jr., Independent Director (Age 54)

Who owns Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (6.07%), Dimensional Fund Advisors LP (1.06%), Prudential Financial Inc. (0.97%), Bank of New York Mellon Corp (0.83%), Russell Investments Group Ltd. (0.76%) and Wells Fargo & Company MN (0.63%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff and Patrick G Enright. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.

Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Mckinley Capital Management LLC Delaware, OxFORD Asset Management LLP, Essex Investment Management Co. LLC, California State Teachers Retirement System, Strs Ohio, Eidelman Virant Capital and Cubist Systematic Strategies LLC. Company insiders that have sold Corcept Therapeutics Incorporated company stock in the last year include David L Mahoney, G Leonard Baker Jr and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Prudential Financial Inc., Dimensional Fund Advisors LP, Old Mutual Global Investors UK Ltd., Ameriprise Financial Inc., Russell Investments Group Ltd., American Century Companies Inc. and Shaker Investments LLC OH. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

How do I buy Corcept Therapeutics Incorporated stock?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics Incorporated's stock price today?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $17.75.

How big of a company is Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated has a market capitalization of $2.03 billion and generates $81.32 million in revenue each year. The biotechnology company earns $8.14 million in net income (profit) each year or $0.29 on an earnings per share basis. Corcept Therapeutics Incorporated employs 103 workers across the globe.

How can I contact Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated's mailing address is 149 Commonwealth Dr, MENLO PARK, CA 94025-1133, United States. The biotechnology company can be reached via phone at +1-650-3273270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics Incorporated (CORT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Corcept Therapeutics Incorporated (NASDAQ:CORT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $19.25 (8.45% upside)

Consensus Price Target History for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Price Target History for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017Piper Jaffray CompaniesSet Price TargetBuy$30.00N/AView Rating Details
8/31/2017Stifel NicolausInitiated CoverageBuy -> Buy$20.00HighView Rating Details
7/18/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$15.00 -> $20.00LowView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Earnings by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018        
11/2/2017Q3 2017$0.13$0.11$41.64 million$42.70 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.08$0.10$31.37 million$35.56 millionViewN/AView Earnings Details
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.47 EPS
Next Year EPS Consensus Estimate: $0.88 EPS

Dividends

Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ CORT)

Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 63.33%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017G Leonard Baker JrDirectorSell30,000$17.59$527,700.00View SEC Filing  
7/19/2017David L MahoneyDirectorSell23,006$12.50$287,575.00View SEC Filing  
7/18/2017David L MahoneyDirectorSell6,091$12.50$76,137.50View SEC Filing  
7/13/2017David L MahoneyDirectorSell6,994$12.50$87,425.00View SEC Filing  
7/12/2017David L MahoneyDirectorSell6,510$12.50$81,375.00View SEC Filing  
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.00View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.00View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.00View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ CORT)

Source:
DateHeadline
Can Valeant (VRX) Turn Around on Rebuilding Initiatives?Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
finance.yahoo.com - November 21 at 5:35 PM
Roche Reports Positive Data From Tecentriq Combination Study ... - NasdaqRoche Reports Positive Data From Tecentriq Combination Study ... - Nasdaq
www.nasdaq.com - November 20 at 11:30 PM
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017
finance.yahoo.com - November 20 at 6:29 PM
Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
finance.yahoo.com - November 20 at 6:29 PM
Corcept Therapeutics Incorporated (CORT) Director Sells $527,700.00 in StockCorcept Therapeutics Incorporated (CORT) Director Sells $527,700.00 in Stock
www.americanbankingnews.com - November 15 at 8:22 PM
The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept TherapeuticsThe Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics
finance.yahoo.com - November 10 at 5:16 PM
5 Stocks That Doubled in 2017 and Can Keep Soaring Higher5 Stocks That Doubled in 2017 and Can Keep Soaring Higher
finance.yahoo.com - November 10 at 5:47 AM
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 8, 2017Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 8, 2017
finance.yahoo.com - November 8 at 9:52 PM
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 6, 2017Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 6, 2017
finance.yahoo.com - November 6 at 6:44 PM
Edited Transcript of CORT earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of CORT earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 4 at 7:09 AM
Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%
finance.yahoo.com - November 4 at 7:09 AM
Corcept Therapeutics Incorporated (CORT) Posts Quarterly  Earnings Results, Beats Estimates By $0.02 EPSCorcept Therapeutics Incorporated (CORT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 3 at 12:46 AM
Corcept misses 3Q profit forecastsCorcept misses 3Q profit forecasts
finance.yahoo.com - November 2 at 11:22 PM
Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate UpdateCorcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - November 2 at 6:22 PM
Small-Cap Biotech Dips As Sales Top, But Earnings Miss By 2 CentsSmall-Cap Biotech Dips As Sales Top, But Earnings Miss By 2 Cents
finance.yahoo.com - November 2 at 6:22 PM
ETFs with exposure to Corcept Therapeutics, Inc. : November 1, 2017ETFs with exposure to Corcept Therapeutics, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 6:19 PM
Theravance Biopharma (TBPH) and Corcept Therapeutics (CORT) Financial ComparisonTheravance Biopharma (TBPH) and Corcept Therapeutics (CORT) Financial Comparison
www.americanbankingnews.com - October 28 at 9:12 PM
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewswire (press release)Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewswire (press release)
globenewswire.com - October 28 at 1:18 AM
Contrasting Corcept Therapeutics (CORT) & Its CompetitorsContrasting Corcept Therapeutics (CORT) & Its Competitors
www.americanbankingnews.com - October 27 at 1:10 AM
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - October 26 at 7:53 PM
First Week Of December 15th Options Trading For Corcept Therapeutics (CORT)First Week Of December 15th Options Trading For Corcept Therapeutics (CORT)
www.thestreet.com - October 26 at 2:53 PM
Corcept Therapeutics Incorporated (CORT) Set to Announce Quarterly Earnings on MondayCorcept Therapeutics Incorporated (CORT) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 9:00 AM
ETFs with exposure to Corcept Therapeutics, Inc. : October 20, 2017ETFs with exposure to Corcept Therapeutics, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 6:53 PM
Todays Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen TherapeuticsToday's Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen Therapeutics
finance.yahoo.com - October 16 at 6:12 PM
Corcept Therapeutics Incorporated (CORT) Stock Rating Reaffirmed by Piper Jaffray CompaniesCorcept Therapeutics Incorporated (CORT) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - October 11 at 3:58 PM
Weakness In Corcept Shares Is Overdone, According To AnalystWeakness In Corcept Shares Is 'Overdone,' According To Analyst
finance.yahoo.com - October 10 at 11:41 PM
Can Corcept Therapeutics Incorporated’s (CORT) ROE Continue To Surpass The Industry Average?Can Corcept Therapeutics Incorporated’s (CORT) ROE Continue To Surpass The Industry Average?
finance.yahoo.com - October 10 at 6:39 PM
Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback PlanMid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan
feeds.benzinga.com - October 10 at 11:38 AM
ETFs with exposure to Corcept Therapeutics, Inc. : October 9, 2017ETFs with exposure to Corcept Therapeutics, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 6:01 PM
Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 5:38 PM
Corcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by BrokeragesCorcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 6:02 PM
Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS RatingStocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating
finance.yahoo.com - October 4 at 4:07 PM
Interesting CORT Put And Call Options For May 2018Interesting CORT Put And Call Options For May 2018
www.nasdaq.com - September 20 at 6:12 PM
4 Biotech Stocks That Show Promise on Sustainable Growth4 Biotech Stocks That Show Promise on Sustainable Growth
finance.yahoo.com - September 14 at 6:15 PM
Reviewing Corcept Therapeutics (CORT) & Cambrex Corporation (CBM)Reviewing Corcept Therapeutics (CORT) & Cambrex Corporation (CBM)
www.americanbankingnews.com - September 11 at 4:10 PM
Corcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by BrokeragesCorcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 2:50 PM
Corcept Therapeutics Incorporated (CORT) PT Raised to $24.00Corcept Therapeutics Incorporated (CORT) PT Raised to $24.00
www.americanbankingnews.com - September 8 at 12:02 PM
Stifel Nicolaus Initiates Coverage on Corcept Therapeutics Incorporated (CORT)Stifel Nicolaus Initiates Coverage on Corcept Therapeutics Incorporated (CORT)
www.americanbankingnews.com - August 31 at 12:34 PM
Pfizers sNDA for Bosulif Accepted in the U.S. and EuropePfizer's sNDA for Bosulif Accepted in the U.S. and Europe
www.nasdaq.com - August 30 at 6:29 PM
Pfizer's sNDA for Bosulif Accepted in the U.S. and EuropePfizer's sNDA for Bosulif Accepted in the U.S. and Europe
finance.yahoo.com - August 30 at 6:28 PM
Top Ranked Momentum Stocks to Buy for August 29thTop Ranked Momentum Stocks to Buy for August 29th
finance.yahoo.com - August 29 at 5:52 PM
Cramers lightning round: I know Im alone here, but I still like the airlinesCramer's lightning round: I know I'm alone here, but I still like the airlines
finance.yahoo.com - August 28 at 10:21 PM
Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock SoarsAdamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
finance.yahoo.com - August 25 at 3:34 PM
Mylan and Otsuka Ink Agreement to Commercialize DeltybaMylan and Otsuka Ink Agreement to Commercialize Deltyba
finance.yahoo.com - August 25 at 3:34 PM
Corcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray CompaniesCorcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - August 24 at 6:28 PM
Aegerion Pharmaceuticals (AEGR) vs. Corcept Therapeutics (CORT) Financial SurveyAegerion Pharmaceuticals (AEGR) vs. Corcept Therapeutics (CORT) Financial Survey
www.americanbankingnews.com - August 21 at 10:26 AM
Todays Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc.Today's Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc.
finance.yahoo.com - August 18 at 5:27 PM
Three Stocks Breaking Out - NasdaqThree Stocks Breaking Out - Nasdaq
www.nasdaq.com - August 18 at 4:45 AM
Three Stocks Breaking OutThree Stocks Breaking Out
finance.yahoo.com - August 16 at 5:50 PM
Three Breakouts, And One Possible Breakdown In CumminsThree Breakouts, And One Possible Breakdown In Cummins
finance.yahoo.com - August 16 at 5:50 PM

Social Media

Financials

Chart

Corcept Therapeutics Incorporated (NASDAQ CORT) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.